-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-002 in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-002 in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-002 in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Drugs In Development, 2023’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bipolar Disorder (Manic Depression) – Drugs In Development, 2023
Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Drugs In Development, 2023’, provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Drugs In Development, 2023’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Major Depressive Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Major Depressive Disorder - Drugs In Development, 2023’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Finerenone in Proteinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Finerenone in Proteinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Finerenone in Proteinuria Drug Details: Finerenone (Kerendia, Firialta) is a nonsteroidal mineralocorticoid. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-001 in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-001 in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-001 in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-001 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-001 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-001 in Alzheimer's Disease Drug Details: Liprosal is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lazucirnon Hydrochloride in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lazucirnon Hydrochloride in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Lazucirnon Hydrochloride in Parkinson's Disease Drug Details:Lazucirnon hydrochloride (ALK-4290) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anakinra in Myocarditis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Myocarditis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Myocarditis Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia...